Reuters logo
BRIEF-Neurocrine announces FDA conditional acceptance of Ingrezza
2016年8月31日 / 晚上8点27分 / 1 年前

BRIEF-Neurocrine announces FDA conditional acceptance of Ingrezza

Aug 31 (Reuters) - Neurocrine Biosciences Inc

* Neurocrine announces FDA conditional acceptance of proprietary name Ingrezza for VMAT2 inhibitor valbenazine

* Expects to receive notification of acceptance of NDA filing, as well as timeframe for NDA review from FDA in October 2016 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below